Propafenone is a class IC antiarrhythmic drug used in the treatment of ventricular
and supraventricular arrhythmias.[1-7] It is primarily a potent sodium
channel blocker, yet also exhibits beta-blocking and calcium channel blocking
activity.[4,6,7] Propafenone
is able to induce important ECG changes, namely prolongation of the PR interval,
bundle branch block, wide QRS and QT intervals, as well as ventricular tachycardia
or bradycardia.[3,4] It may be associated with significant
proarrhythmogenic effects, even at therapeutic doses.[2] A fatal overdose on propafenone is usually
attributed to conduction abnormalities, leading to asystole or electromechanical
dissociation. The authors describe two clinical cases of propafenone intoxication
with life-threatening ECG changes, but with a favorable final outcome.
Case Report
Case 1
Female patient, 44 years old, with no relevant medical history. The patient was
brought to the Emergency Room (ER) following voluntary ingestion of 4500mg of
propafenone. While being brought to the ER, the patient had a short-lasting
seizure, later regaining consciousness. Upon arrival at the ER, she had a
Glasgow Coma Scale (GCS) score of 10 (Eye-3, Motor-5, Verbal-2), bradycardic
(55bpm) and hypotensive (Blood Pressure [BP] 85/30mmHg). Clinical examination
was unremarkable. Gastric lavage was performed, with removal of what seemed to
be pill residuals. Blood work revealed metabolic acidosis. The ECG at admission
showed sinus arrhythmia, with right axis deviation, incomplete right bundle
branch block (RBBB) and unspecific repolarization changes in DIII, V1 and V2.
The PR, QRS and QT intervals were within normal range (Figure 1). BP did not respond to aggressive fluid therapy,
thus a dopamine perfusion was started. After approximately an hour of beginning
treatment, the patient suffered a tonic-clonic seizure accompanied by extreme
bradycardia and widening of the QRS. Unfortunately, due to the urgency of the
situation and the critical state of the patient, these electrical changes could
not be recorded through standard 12-lead ECG. She was medicated with atropine
and benzodiazepine. This resulted in a comatose state (Glasgow scale of 3),
worsening of metabolic acidosis and respiratory failure. The patient was
intubated, placed on continuous mechanical ventilation and admitted to the
Intensive Care Unit (ICU).
Figure 1
ECG on admission from case 1.
ECG on admission from case 1.Upon admission to the ICU, rhythm strip monitoring revealed atrial fibrillation
with occasional sinus activity, along with a widening of the QRS (200
milliseconds) interval. Three hours later, sinus rhythm was restored and QRS
interval returned to normal values, with an almost complete disappearance of the
RBBB pattern. In the first 6 hours after admission, there was a progressive
hemodynamic and clinical stabilization, allowing for a gradual weaning from
aminergic and ventilator support. On day two, the patient was conscious and
hemodynamically stable. She was discharged after a psychiatric consultation.
Case 2
Female patient, 56 years old, with a history of Atrial Fibrillation and major
depressive disorder medicated with propafenone 150 mg twice daily and duloxetine
60 mg once daily. The patient was first observed in a small community hospital
after voluntarily ingesting 3000mg of propafenone. At that institution, on
arrival, the patient was initially fully awake and gastric lavage was begun.
However, shortly afterwards, she developed a tonic-clonic seizure, followed by
two episodes of cardiac arrest due to extreme bradycardia. Resuscitation was
achieved after less than 2 minutes of advanced life support and atropine
administration. After ensuring hemodynamic and electrical stability, the patient
was transported to a centralized hospital. Upon admission, she was bradycardic
(50 bpm), normotensive (BP 139/89 mmHg), and with a GCS score of 14 (Eye 4,
Motor 6, Verbal 4). ECG revealed a junctional rhythm, with a type-1 Brugada
pattern in V1 to V3 leads (Figure 2). The
patient was admitted to the Cardiac Intensive Care Unit for monitoring. After 24
hours of clinical, hemodynamic and electrical stability, a new ECG was
performed, revealing sinus rhythm and disappearance of the Brugada pattern.
Figure 2
ECG from second clinical case revealing type-1 Brugada pattern.
ECG from second clinical case revealing type-1 Brugada pattern.
Discussion
Propafenone is a Vaughan Williams Class IC antiarrhythmic agent, and thus a potent
sodium channel blocker.[1,3,4,6,7] It also exhibits beta-blocking and calcium channel
blocking activity.[4,6,7]Nearly 100%
of propafenone is absorbed. However, because of a first-pass hepatic elimination
effect, its bioavailability is unpredictable.[1,4] Propafenone is
metabolized into two major metabolites: 5-hydroxypropafenone and norpropafenone, a
process genetically determined by the CYP2D6 enzyme system.[1,4] The propafenone elimination half-time varies depending on
whether the patient is a poor or an extensive metabolizer.[1,4] There are
several infrequent adverse reactions, such as hematologic (agranulocytosis),
gastrointestinal, hepatic and neurological (convulsions, amnesia, peripheral
neuropathy and exacerbation of myasthenia) reactions.[2] A number of clinical signs and symptoms have been
associated with propafenone intoxication, ranging from nausea and vomiting to
seizures, coma, respiratory depression and cardiovascular collapse (Table 1).[4] Propafenone may be responsible for several ECG changes,
including sinus bradycardia, sinus arrest, atrial fibrillation, prolongation of the
PR interval, intraventricular conduction abnormalities (QRS and QT widening and
right bundle branch block), Brugada pattern,[8-11] ventricular
tachycardia, ventricular flutter or fibrillation and cardiac arrest.[1,4]
Table 1
Clinical Signs and Symptoms of Propafenone Intoxication, adapted from Clarot
et al[4]
Nausea
Vomiting
Metabolic acidosis
Blurred vision and sleepiness
Hypotonia
Seizure
Respiratory depression
Coma
Sinus Bradycardia
Sinus arrest
Atrial Fibrillation
AV Block
Intraventricular conduction disorders (QRS widening,
Right Bundle Block)
Hypotension
Acute load of the right ventricle
Cardiac failure
Cardiovascular collapse
Cardiac arrest
Clinical Signs and Symptoms of Propafenone Intoxication, adapted from Clarot
et al[4]The authors describe two cases of voluntary ingestion of excessive doses of
propafenone, both with successful outcomes. There is no specific treatment. A timely
gastric lavage was attempted in both cases. When performed promptly, gastric lavage
is the only effective way of eliminating excessive doses of propafenone.[1,3]In both cases, tonic-clonic seizures were observed. This is an important neurological
manifestation of propafenone intoxication.[3,4] The reason for
seizure occurrence is uncertain. Saz et al.[3] and Clarot et al.[4] suggest that it may be attributed either to a direct toxic
effect of propafenone or to cerebral hypoperfusion caused by arrhythmia or
conduction disturbance.In the first case, all the major clinical warning signs were observed: cardiac
failure, conduction disturbance, and seizures.[4] There was a progressive worsening of the neurological and
respiratory status. The patient eventually became comatose, requiring mechanical
ventilation. Cardiac failure was also observed, resulting in arterial hypotension,
and requiring catecholaminergic support with positive inotropic and vasoconstrictive
drugs. After progressive elimination of the drug, weaning from supportive measures
was fairly straightforward. Another important aspect is the dynamic ECG changes. The
patient underwent rhythm changes (going from sinus arrhythmia to atrial fibrillation
and finally returning to normal sinus rhythm) and intraventricular conduction
disorders (with widening of the QRS interval and enhancement of the RBBB pattern).
These changes occurred only in the first 3 hours after admission, corresponding to
peak serum concentration.[4] This
highlights the importance of close monitoring and prompt treatment in the first
hours following propafenoneoverdose.In the second case, the ingestion of supratherapeutic levels of propafenone revealed
a Brugada type 1 pattern on surface ECG. Concealed or intermittent forms of the
Brugada Syndrome have been described in a few subset of patients, namely following
hyperventilation, beta-adrenergic blockade and alpha-adrenergic stimulation,
muscarinic receptors stimulation, and sodium channels blockade inducing or
increasing ST elevation.[10,11] In this particular case,
propafenone is able to unmask the concealed Brugada phenomenon due to its sodium
channel and beta-adrenergic blocking activity.[10] The appearance of the Brugada pattern in response to type
IC antiarrhythmic drugs does not seem to be associated with a great risk for
polymorphic arrhythmias; however, further investigation is needed.[11] In this case, the Brugada pattern
disappeared after drug elimination.Both patients were closely monitored for 36 to 48 hours. The propafenone elimination
half-time ranges from 17 ± 8 hours for poor metabolizers to 5±2 hours
for extensive metabolizers,[1,4] thus monitoring over that period of
time is required. Peak serum concentration occurs between 2 and 3 h after
ingestion,[4] during which
time the most life-threatening ECG changes may occur.Both cases are paradigmatic in how unpredictable propafenoneoverdosing can be. It
can range from an almost benign set of symptoms to a catastrophic presentation
resulting in death. The first case presented the most important clinical warning
signs, namely cardiac failure, conduction disturbance, and seizures. However, thanks
to immediate treatment, the patient survived. The second case was critical as well,
considering the seizing and extreme bradycardia requiring advanced life support;
however, after the initial catastrophic presentation, clinical stability was
maintained throughout the following hours. Another interesting aspect was the fact
that a type-1 Brugada pattern was revealed. In both cases, no direct treatment for
propafenone intoxication was available. Close monitoring and prompt supportive
measures are crucial in assuring a good outcome